AUNP-12, a peptide patented in 2014, was the first peptide-based inhibitor targeting the PD-1/PD-L1 interaction, showing promising results to reduce tumour proliferation and metastasis in preclinical animal studies (36). The gene discussed is CD274; the disease is neoplasm.